SCHEMBL2658058

SCHEMBL2658058

COc1ccc(Cc2nsc(C(N)=O)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
PARP10 Q53GL7 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
PARP4 Q9UKK3 1/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP2D6 P10635 1/20 0.42
ATM Q13315 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
LTA4H P09960 1/20 0.41
POLB P06746 2/20 0.41
CYP3A4 P08684 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1081345 0.78 ALDH1A1 (0.53) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6529435 0.76 LTA4H (0.46) LMNAMAPTSMN1; SMN2NPSR1ALDH1A1
SCHEMBL9107820 0.75 ADORA3 (0.58) MAPTSMN1; SMN2PARP10CA1CA2
SCHEMBL1020013 0.75 MAPT (0.49) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL29567644 0.72 VNN1 (0.55) MAPTNPC1RAB9ASMN1; SMN2PARP10
SCHEMBL3083749 0.72 L3MBTL1 (0.53) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL8213818 0.71 PARP10 (0.78) LMNANPC1RAB9ASMN1; SMN2PARP10
SCHEMBL1019458 0.70 MAPT (0.43) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1019459 0.69 SLC6A4 (0.44) LMNAMAPTALDH1A1CYP2D6ATM
SCHEMBL1023567 0.69 MAPT (0.42) LMNAMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP claimed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US claimed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US claimed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO claimed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 LMNA 3936/4885MAPT 4151/4885NPC1 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.